Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
PLoS One ; 16(5): e0251644, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33984060

RESUMO

OBJECTIVES: Comprehensive cost-effectiveness analyses of introducing varicella and/or herpes zoster vaccination in the Swedish national vaccination programme. DESIGN: Cost-effectiveness analyses based on epidemiological results from a specifically developed transmission model. SETTING: National vaccination programme in Sweden, over an 85- or 20-year time horizon depending on the vaccination strategy. PARTICIPANTS: Hypothetical cohorts of people aged 12 months and 65-years at baseline. INTERVENTIONS: Four alternative vaccination strategies; 1, not to vaccinate; 2, varicella vaccination with one dose of the live attenuated vaccine at age 12 months and a second dose at age 18 months; 3, herpes zoster vaccination with one dose of the live attenuated vaccine at 65 years of age; and 4, both vaccine against varicella and herpes zoster with the before-mentioned strategies. MAIN OUTCOME MEASURES: Accumulated cost and quality-adjusted life years (QALY) for each strategy, and incremental cost-effectiveness ratios (ICER). RESULTS: It would be cost-effective to vaccinate against varicella (dominant), but not to vaccinate against herpes zoster (ICER of EUR 200,000), assuming a cost-effectiveness threshold of EUR 50,000 per QALY. The incremental analysis between varicella vaccination only and the combined programme results in a cost per gained QALY of almost EUR 1.6 million. CONCLUSIONS: The results from this study are central components for policy-relevant decision-making, and suggest that it was cost-effective to introduce varicella vaccination in Sweden, whereas herpes zoster vaccination with the live attenuated vaccine for the elderly was not cost-effective-the health effects of the latter vaccination cannot be considered reasonable in relation to its costs. Future observational and surveillance studies are needed to make reasonable predictions on how boosting affects the herpes zoster incidence in the population, and thus the cost-effectiveness of a vaccination programme against varicella. Also, the link between herpes zoster and sequelae need to be studied in more detail to include it suitably in health economic evaluations.


Assuntos
Vacina contra Varicela/administração & dosagem , Varicela/prevenção & controle , Vacina contra Herpes Zoster/administração & dosagem , Herpes Zoster/prevenção & controle , Programas de Imunização/economia , Adolescente , Adulto , Idoso , Varicela/economia , Varicela/epidemiologia , Varicela/transmissão , Vacina contra Varicela/economia , Criança , Pré-Escolar , Análise Custo-Benefício , Herpes Zoster/economia , Herpes Zoster/epidemiologia , Herpes Zoster/transmissão , Vacina contra Herpes Zoster/economia , Herpesvirus Humano 3/imunologia , Herpesvirus Humano 3/patogenicidade , Humanos , Programas de Imunização/métodos , Programas de Imunização/estatística & dados numéricos , Incidência , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Modelos Biológicos , Modelos Econômicos , Anos de Vida Ajustados por Qualidade de Vida , Suécia/epidemiologia , Resultado do Tratamento , Ativação Viral , Adulto Jovem
2.
Przegl Epidemiol ; 69(4): 693-7, 841-3, 2015.
Artigo em Inglês, Polonês | MEDLINE | ID: mdl-27139346

RESUMO

BACKGROUND: Incidence of shingles in different regions of the world ranged from 300 to 500/100,000 persons, and in the population older than 80 years of age reaches more than 1000/100,000. In the age group 50+ the incidence is enough high to be a serious medical and economic burden. Lack of details about the incidence and frequency of complications in Polish population let us too made an attempt to assess the scale of the problem, among others to the purpose of the evaluation of the legitimacy of implementing vaccination in the 50+ population. METHODS: First, based on coming data from the Swietokrzyskie Province Division of the National Health Fund we judged the incidence of shingles in this province in 2013 in individual ancient groups and depending on detailed diagnoses and with the division into the basic health, clinic and hospital care. Second, based on gathered data through NIZP-PZH, we judged hospital morbidity connected with shingles in Poland in 2008-2012 years, in individual ancient groups. RESULTS: Extrapolating the data from the Swietokrzyskie province we assess the incidence of shingles on average 338.8/100,000. She is tallest in the age group 50+ (614.3/100,000) and in this group also the most complications are being observed. Hospital morbidity in entire Poland showed in 2008-2012 years the frequency on average 4.93-5.42/100,000, in the group of 0-19 years; 0.10-1.50/100,000, in the group of 20-49 years; 4.9-5.42/100,000 and in the 50+ group--9.99-13.37/100,000. CONCLUSIONS: (1) Shingles, especially in the 50+ age group, constitutes a serious health problem in Poland, being a cause of numerous advices in basic health care and at clinics in Poland, as well of numerous hospitalizations and dangerous complications. (2) It seems, that active immunization against shingles, especially of 50+ persons, would be a favourable solution from the individual, as well as public perspective.


Assuntos
Efeitos Psicossociais da Doença , Vacina contra Herpes Zoster/economia , Herpes Zoster/economia , Herpes Zoster/epidemiologia , Neuralgia Pós-Herpética/economia , Neuralgia Pós-Herpética/epidemiologia , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Análise Custo-Benefício , Feminino , Custos de Cuidados de Saúde , Herpes Zoster/prevenção & controle , Vacina contra Herpes Zoster/uso terapêutico , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Programas Nacionais de Saúde/economia , Neuralgia Pós-Herpética/prevenção & controle , Polônia/epidemiologia , Medição de Risco
3.
J Tradit Chin Med ; 32(1): 125-8, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22594116

RESUMO

OBJECTIVE: To analyze the cost effect of surrounding acupuncture plus electric acupuncture, cotton-sheet moxibustion, puncturing with red-hot needles, tapping plus cupping on herpes zoster. METHODS: Five hundred patients with herpes zoster were randomly divided into group A (surrounding acupuncture plus electric acupuncture), group B (cotton-sheet moxibustion), group C (puncturing with red-hot needles), group D (tapping plus cupping), and group E (Western medicine). The treatment was carried out twice a day in group E and once a day in the other four groups. The curative effect was observed on the 10th day of treatment; the cost was calculated for the five therapies, and the cost-effect ratio (C/E) and increment ratio (delta C/delta E) were analyzed. RESULTS: After the 10-day treatment, there was no statistical difference (P > 0.05) in the curative effect among the five groups. Pain being alleviated one day faster than in group E amounted to a saving of RMB 21.90 yuan in group A, a saving of RMB 21.87 yuan in group B, a saving of RMB 26.00 yuan in group C, and a saving of RMB 20.23 yuan in group D. Compared with group C, the values of delta C/delta E were RMB 1.55, 2.81, and 0.21 yuan in groups A, B, and D, respectively. CONCLUSIONS: The curative effect in groups A, B, C, and D was similar to that in group E, but the C/E was better than in group E.


Assuntos
Terapia por Acupuntura/economia , Herpes Zoster/terapia , Moxibustão/economia , Manejo da Dor/economia , Terapia por Acupuntura/métodos , Adulto , Idoso , Feminino , Herpes Zoster/economia , Humanos , Masculino , Pessoa de Meia-Idade , Moxibustão/métodos , Manejo da Dor/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA